Hotta Osamu
Department of Nephrology, Sendai Shakaihoken Hospital, Sendai, Japan.
Acta Otolaryngol Suppl. 2004 Dec(555):43-8. doi: 10.1080/03655230410003387.
As IgA nephropathy (IgAN) was originally regarded as a benign condition, the indication of corticosteroids has been highly restricted because of their side effects, and has been used for a specific subgroup of IgAN patients with consideration of the risk/benefit ratio. During the last decade, however, with the recognition that the overall long-term prognosis of IgAN is a non-benign condition, more aggressive treatments, including high dose corticosteroids and tonsillectomy, have been used for a wider subgroup of patients with IgAN. Since 1988, we have treated IgAN patients with steroid semi-pulse therapy combined with tonsillectomy. Over 500 patients with IgAN have been treated with this treatment protocol, and a high percentage of patients enter clinical remission, i.e. free from urinary abnormalities if the combination therapy was initiated in its early stage. Through these experiences we think the goal of treatment of IgAN patients should be changed from "slowing the progression of nephropathy" to "clinical remission".
由于IgA肾病(IgAN)最初被视为一种良性疾病,考虑到其副作用,糖皮质激素的使用指征受到严格限制,仅用于特定亚组的IgAN患者,并需权衡风险/获益比。然而,在过去十年中,随着认识到IgAN的总体长期预后并非良性,更积极的治疗方法,包括高剂量糖皮质激素和扁桃体切除术,已被应用于更广泛的IgAN患者亚组。自1988年以来,我们采用类固醇半脉冲疗法联合扁桃体切除术治疗IgAN患者。超过500例IgAN患者接受了该治疗方案,并且如果在疾病早期开始联合治疗,很大比例的患者可实现临床缓解,即无尿液异常。通过这些经验,我们认为IgAN患者的治疗目标应从“延缓肾病进展”转变为“临床缓解”。